The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy
Open accessAbstract
Although low absolute values of bone mineral density (BMD) predict increased fracture risk in osteoporosis, it is not certain how well increases in BMD with antiresorptive therapy predict observed reductions in fracture risk. This work examines the relationships between changes in BMD after 1 year or 3 years of raloxifene or placebo therapy and the risk for new vertebral fractures at 3 years. In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 7705 postmenopausal women with osteoporosis were randomized to placebo or raloxifene 60 mg/day or 120 mg/day. Relationships between baseline BMD and changes in BMD from baseline with the risk of new vertebral fractures were analyzed in this cohort using logistic regression models with the raloxifene doses pooled. As has been observed in other populations, women with the lowest baseline lumbar spine or femoral neck BMD in the MORE cohort had the greatest risk for vertebral fractures. Furthermore, for any percentage change, either increase or decrease in femoral neck or lumbar spine BMD at 1 year or 3 years, raloxifene-treated patients had a statistically significantly lower vertebral fracture risk compared with placebo-treated patients. The decrease in fracture risk with raloxifene was similar across the range of percentage change in femoral neck BMD observed at 3 years; patients receiving raloxifene had a 36% lower risk of vertebral fracture compared with those receiving placebo. At any percentage change in femoral neck and lumbar spine BMD observed at 1 year, raloxifene treatment decreased the risks of new vertebral fractures at 3 years by 38% and 41%, respectively. The logistic regression model showed that the percentage changes in BMD with raloxifene treatment accounted for 4% of the observed vertebral fracture risk reduction, and the other 96% of the risk reduction remains unexplained. The present data show that the measured BMD changes observed with raloxifene therapy are poor predictors of vertebral fracture risk reduction with raloxifene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Bone density at various sites for prediction of hip fractures
Cummings, S. R., Browner, W., Cummings, S. R., Black, D. M., Nevitt, M. C., Browner, W., Genant, H. K., Cauley, J., Ensrud, K., Scott, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92555-8 · Cited by 2,446
Self-citationRisk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,897
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women
Ross, P. D., Davis, J. W., Epstein, R. S., & Wasnich, R. D. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-11-919 · Cited by 1,107
Long-term fracture prediction by bone mineral assessed at different skeletal sites
Dr. Melton, L. J., Atkinson, E. J., O'Fallon, W. M., Wahner, H. W., & Riggs, B. L. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081010 · Cited by 862
Black, D. M., Arden, N. K., Palermo, L., Pearson, J., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.5.821 · Cited by 800
Self-citation
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“For raloxifene, the percentage changes in BMD accounted for 4% of the observed vertebral fracture risk reduction [341].”
BackgroundEpidemiology, etiology, and diagnosis of osteoporosis
Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,293
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., Rizzoli, R., & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 776
Ensrud, K. E., & Crandall, C. J. (2017) · Annals of Internal Medicine · doi:10.7326/aitc201708010 · Cited by 726
Marx, R. E., Cillo, J. E., & Ulloa, J. J. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2007.08.003 · Cited by 720
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588
Khosla, S. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.01.054 · Cited by 564
Delmas, P. D., Genant, H. K., Crans, G. G., Stock, J. L., Wong, M., Siris, E., & Adachi, J. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00241-2 · Cited by 545
Self-citationSilverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 508
Pathophysiology of Osteoporosis
Armas, L. A. G., & Recker, R. R. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.006 · Cited by 466
Kendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
Bone Quality: The Determinants of Bone Strength and Fragility
Fonseca, H., Moreira-Gonçalves, D., Coriolano, H.-J. A., & Duarte, J. A. (2014) · Sports Medicine · doi:10.1007/s40279-013-0100-7 · Cited by 429
Riggs, B. L., & Parfitt, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 380
Body, J.-J., Gaich, G. A., Scheele, W. H., Kulkarni, P. M., Miller, P. D., Peretz, A., Dore, R. K., Correa-Rotter, R., Papaioannou, A., Cumming, D. C., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020334 · Cited by 365
The Assessment of Fracture Risk
Unnanuntana, A., Gladnick, B. P., Donnelly, E., & Lane, J. M. (2010) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/jbjs.i.00919 · Cited by 361
Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Recker, R., Lappe, J., Davies, K. M., & Heaney, R. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040710 · Cited by 343
Felsenberg, D., & Boonen, S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.020 · Cited by 341
Prevention and management of osteoporosis
McClung, M. R. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(02)00080-5 · Cited by 321
Hip Fractures and the Contribution of Cortical Versus Trabecular Bone to Femoral Neck Strength
Holzer, G., von Skrbensky, G., Holzer, L. A., & Pichl, W. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081108 · Cited by 319
A biomechanical perspective on bone quality
Hernandez, C. J., & Keaveny, T. M. (2006) · Bone · doi:10.1016/j.bone.2006.06.001 · Cited by 319
Heaney, R. P. (2003) · Bone · doi:10.1016/s8756-3282(03)00236-9 · Cited by 306
Delmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294
Bolotin, H. H. (2007) · Bone · doi:10.1016/j.bone.2007.02.022 · Cited by 274
“[61], who found fracture risk actually declined for those displaying diminished (BMD)DXA with raloxifene therapy, and in light of the much earlier study of Riggs et al.”
ResultBiochemical markers of bone turnover – uses and limitations
Hlaing, T. T., & Compston, J. E. (2014) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563213515190 · Cited by 265
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254
Bone tissue compositional differences in women with and without osteoporotic fracture
McCreadie, B. R., Morris, M. D., Chen, T.-C., Sudhaker Rao, D., Finney, W. F., Widjaja, E., & Goldstein, S. A. (2006) · Bone · doi:10.1016/j.bone.2006.06.008 · Cited by 253
Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Self-citationSalmon calcitonin: a review of current and future therapeutic indications
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0490-1 · Cited by 216
“As an example, post hoc analyses from the MORE study [54] have demonstrated a striking discordance between changes in BMD and treatment associated fracture risk reduction.”
MethodSelective estrogen receptor modulators: an update on recent clinical findings
Shelly, W., Draper, M. W., Krishnan, V., Wong, M., & Jaffe, R. B. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31816400d7 · Cited by 193
Self-citationChesnut, C. H., Majumdar, S., Newitt, D. C., Shields, A., Van Pelt, J., Laschansky, E., Azria, M., Kriegman, A., Olson, M., Eriksen, E. F., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050411 · Cited by 163
Levy, C., Harnois, D. M., Angulo, P., Jorgensen, R., & Lindor, K. D. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01026.x · Cited by 62
Villareal, D. T., Kotyk, J. J., Armamento‐Villareal, R. C., Kenguva, V., Seaman, P., Shahar, A., Wald, M. J., Kleerekoper, M., & Fontana, L. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00643.x · Cited by 51
“…that in osteoporotic patients, bisphosphonate therapy results in a rapid reduction in markers of bone turnover and bone remodelling, and in a 30–40% reduction in fracture risk, even in the absence of any change in bone mass (Bjarnason et al., 2001; Cummings et al., 2002; Sarkar et al., 2002).”
BackgroundResultInfluentialJadzic, J., Milovanovic, P., Tomanovic, N., Zivkovic, V., Djukic, D., Nikolic, S., Djuric, M., & Djonic, D. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02130-3 · Cited by 11
“The importance of assessing bone quality is emphasized by the fact that some pharmaceutic agents could improve bone strength and reduce fracture risk without increasing BMD [23, 24], indicating its potential to develop new treatment options [25].”
Testosterone Therapy for Osteoporosis in Men
Lakshman, K. M., Bhasin, S., & Araujo, A. B. (2010) · Osteoporosis in Men · doi:10.1016/b978-0-12-374602-3.00056-0 · Cited by 1
Metadata
- Authors
- Sarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M., & Harper, K. D.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 17
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1985160737
- Cited by
- 442
- References
- 30
- FWCI
- 42.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.